Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03224910 · ClinicalTrials.gov registry record

Diagnostic Efficiency of Touch Imprints Versus Smears

A clinical trial, sponsored by University of Mississippi Medical Center.

Completed
Registry status
47
Enrollment target

NCT03224910: Completed study, sponsored by University of Mississippi Medical Center.

NCT03224910 is a clinical trial that has completed, run by University of Mississippi Medical Center. The registered enrollment target is 47 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03224910 has completed, sponsored by University of Mississippi Medical Center.

COMPLETED
Registry status
47 participants
Enrollment target

Study Summary

Cytopathologists work along with radiologist in the diagnosis of lesions. Rapid on site interpretation (ROSE) of fine needle aspiration (FNA) smears of radiologically suspicious lesions is a common clinical practice. In the last years, the investigators have seen trend towards needle core biopsies of radiologically suspicious lesions. The investigators want to analyze the challenges of rapid on site interpretation of touch imprints (TI) of needle core biopsies (NCB) versus fine needle aspiration smears.

Primary Outcome

All the cytology cases with rapid on site examination (ROSE) of FNA smears and/or touch imprints of needle core biopsies from January 1st/2011 to December 31st/ 2017, will be retrieved using the University of Mississippi Medical Center's Pathology Laboratory information system (Copath). The investigators will review the cases and get a number of cases with enough diagnostic features (based on the cytomorphologic features of the cells, quality of the smears and touch imprints, and the cellularity

Interventions

  • OTHER Cytologic techniques used for rapid on site interpretation

Trial Details

FieldValue
Enrollment Target 47 participants
Start Date 2017-07-18
Est. Completion 2018-05-02

What the finished NCT03224910 record still lists

NCT03224910 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 47 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which Cytologic techniques used for rapid on site interpretation is the first listed.

NCT03224910 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03224910 about?

NCT03224910 is a clinical study titled "Diagnostic Efficiency of Touch Imprints Versus Smears". Cytopathologists work along with radiologist in the diagnosis of lesions. Rapid on site interpretation (ROSE) of fine needle aspiration (FNA) smears of radiologically suspicious lesions is a common clinical practice. In the last years, the investigators have seen trend towards needle core biopsies o...

What is the current status of trial NCT03224910?

This trial is currently completed. The enrollment target is 47 participants. The study started on 2017-07-18. Estimated completion is 2018-05-02.

What interventions are being tested in trial NCT03224910?

The interventions under investigation include: Cytologic techniques used for rapid on site interpretation (OTHER).

Who is sponsoring clinical trial NCT03224910?

This trial is sponsored by University of Mississippi Medical Center, which has 96 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03313011 · 47 participants

    The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech

  • NCT03467516 · 47 participants · Phase 2

    Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma

  • NCT03886662 · 47 participants · Phase 1

    A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)

  • NCT04013802 · 47 participants · Phase 1

    TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03224910, the US trial registry maintained by the National Library of Medicine. NCT03224910 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.